Contact Us

You can contact us by email or tel.

Search

Recent Comments

[China BD 2024] [China Biotech M&A] Biotheus and BioNTech Enters an Acquisition on PD-L1/VEGF-A BsAbs PM8002 (BNT327) – CninMed – China Innovative Drugs Update on [China BD 2023] Biotheus and BioNTech Enters the License on PD-L1/VEGF-A BsAbs PM8002 (BNT327)
[Technology Collaboration] MediLink and BioNTech Expand the Collaboration on several ADC products – CninMed – China Innovative Drugs Update on [China BD 2023] MediLink and BioNTech enters a 1 billion USD License on HER3 ADC YL202 (BNT326)
[China Original Asset] BioNTech and BMS enters a 11.1 billion USD Collaboration on PD-L1xVEGF-A BsAbs BNT327 (PM8002 from Biotheus) – CninMed – China Innovative Drugs Update on [China BD 2024] [China Biotech M&A] Biotheus and BioNTech Enters an Acquisition on PD-L1/VEGF-A BsAbs PM8002 (BNT327)
admin on [China BD Deal] TUL and Novo Nordisk enters a 2 billion USD license for UBT251, a GLP-1/GIP/glucagon triple receptor agonist